Guardant Health (FRA:5GH) ROCE % : -29.79% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guardant Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Guardant Health's annualized ROCE % for the quarter that ended in Mar. 2024 was -29.79%.

Guardant Health ROCE % Historical Data

The historical data trend for Guardant Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health ROCE % Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-9.67

-15.17

-18.82

-39.44

-31.34

Guardant Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-38.74	-19.35	-21.34	-46.95	-29.79

Guardant Health ROCE % Calculation

Guardant Health's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-436.663	/	( ( (1519.826 - 182.4)	+	(1638.148 - 188.826) )	/ 2 )
	=	-436.663	/	( (1337.426	+	1449.322)	/ 2 )
	=	-436.663	/	1393.374
	=	-31.34 %

Guardant Health's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-419.28	/	( ( (1638.148 - 188.826)	+	(1568.23 - 202.408) )	/ 2 )
	=	-419.28	/	( ( 1449.322	+	1365.822 )	/ 2 )
	=	-419.28	/	1407.572
	=	-29.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Guardant Health (FRA:5GH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Guardant Health ROCE % Related Terms

Thank you for viewing the detailed overview of Guardant Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (FRA:5GH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GH:USA

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines